TrialJournal of clinical pharmacology2019

Moderate Renal Impairment Does Not Impact the Ability of CSL112 (Apolipoprotein A-I [Human]) to Enhance Cholesterol Efflux Capacity.

Andreas Gille et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.